Physician profile
Blanca L Gray
NPI 1811905789
$3,683.16
in general payments reported to CMS, 2019-2025
24 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $115 · 2021: $27.05 · 2022: $101 · 2024: $1,161 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.06 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $839.32 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $510.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $355.47 | 2019-2025 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $252.41 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $208.55 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $191.68 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $172.03 | 2024 | |
| Exact Sciences Corporation | $154.03 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.10 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $115.10 | 2020 | |
| Sanofi-Aventis U.S. LLC | $109.18 | 2019 | |
| Terumo Medical Corporation | $94.34 | 2025 | Azur Cx Detachable |
| Pfizer INC. | $91.13 | 2019-2025 | |
| Lundbeck LLC | $85.80 | 2024-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $75.17 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $75.12 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $53.35 | 2019 | |
| Allergan, INC. | $44.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.21 | 2019 | |
| Inspire Medical Systems, INC. | $20.72 | 2025 | Inspire |
| Abbvie INC. | $16.23 | 2024 | |
| Sumitomo Pharma America, INC. | $15.53 | 2025 | Gemtesa |
| Medtronic, INC. | $14.79 | 2025 | Synchromedii |
| Janssen Pharmaceuticals, INC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blanca Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.